Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Rohto Pharmaceutical CoRPHCF 89 Debt-to-EBITDA is 0.58 as of Mar. 2026, which is 123% above its 10-year median of 0.26. GuruFocus rates RPHCF with a GF Score™ of 89/100 and a GF Value™ of $21.04. The stock has 2 warning signs investors should review. Among 1,549 Consumer Packaged Goods companies, Rohto Pharmaceutical Co ranks better than 69.4% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Rohto Pharmaceutical Co's Debt-to-EBITDA or its related term are showing as below:
RPHCF'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.21 Med: 0.26 Max: 1.03
Current: 0.92
During the past 13 years, the highest Debt-to-EBITDA Ratio of Rohto Pharmaceutical Co was 1.03. The lowest was 0.21. And the median was 0.26.
RPHCF's Debt-to-EBITDA is ranked better than 69.4% of 1549
companies
in the Consumer Packaged Goods industry
Industry Median: 2.08
vs RPHCF: 0.92
Rohto Pharmaceutical Co (OTCPK:RPHCF) Debt-to-EBITDA Explanation
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Rohto Pharmaceutical Co Debt-to-EBITDA Related Terms
Rohto Pharmaceutical Co Debt-to-EBITDA Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Household & Personal Products subindustry, Rohto Pharmaceutical Co's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Rohto Pharmaceutical Co Debt-to-EBITDA vs Consumer Packaged Goods Industry
For the Consumer Packaged Goods industry and Consumer Defensive sector, Rohto Pharmaceutical Co's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Rohto Pharmaceutical Co's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Mar. 2026) EBITDA data.
Rohto Pharmaceutical Co (RPHCF) has a Debt-to-EBITDA of 0.58 as of Mar. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Rohto Pharmaceutical Co. This is 123% above median its historical median of 0.26. Over the past decade, Rohto Pharmaceutical Co's Debt-to-EBITDA has ranged from 0.21 to 1.03. According to the industry distribution chart, Rohto Pharmaceutical Co ranks #474 out of 1549 companies in the Consumer Packaged Goods industry, placing it in the top 30.6%.
Is Rohto Pharmaceutical Co's Debt-to-EBITDA too high?
Rohto Pharmaceutical Co's current Debt-to-EBITDA of 0.58 is 123% above median its 10-year median of 0.26. Over the past 10 years, this metric has ranged from a low of 0.21 to a high of 1.03. The Consumer Packaged Goods industry median Debt-to-EBITDA is 2.08. Rohto Pharmaceutical Co's value of 0.58 is 72.1% below this industry median. Based on the distribution chart, Rohto Pharmaceutical Co ranks #474 out of 1549 companies in the Consumer Packaged Goods industry, which is above the industry midpoint. Overall, Rohto Pharmaceutical Co has a GF Score™ of 89/100, reflecting its overall financial health beyond just this single metric.
How does Rohto Pharmaceutical Co's Debt-to-EBITDA compare to PG and CL?
According to the Consumer Packaged Goods industry distribution chart, Rohto Pharmaceutical Co ranks #474 out of 1549 companies for Debt-to-EBITDA. This puts Rohto Pharmaceutical Co in the upper half of its industry. The industry median Debt-to-EBITDA is 2.08. Rohto Pharmaceutical Co's value of 0.58 is 72.1% below this benchmark. Historically, Rohto Pharmaceutical Co's own Debt-to-EBITDA has ranged from 0.21 to 1.03 over the past decade. While the company's 10-year median is 0.26 vs. the industry median of 2.08, Rohto Pharmaceutical Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Consumer Packaged Goods company?
The median Debt-to-EBITDA among Consumer Packaged Goods companies is 2.08, based on 1,549 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Rohto Pharmaceutical Co's current Debt-to-EBITDA of 0.58 is 72.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Rohto Pharmaceutical Co. For the Consumer Packaged Goods industry, the median Debt-to-EBITDA is 2.08 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Rohto Pharmaceutical Co's current Debt-to-EBITDA is 0.58, which is 123% above median its own 10-year median of 0.26. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rohto Pharmaceutical Co stock overvalued right now?
Rohto Pharmaceutical Co (RPHCF) has a current Debt-to-EBITDA of 0.58. The stock's GF Value™ is $21.04, compared to a current price of $15.00 — trading 28.7% below its estimated fair value. The current Debt-to-EBITDA is 0.58, which is 123% above median its 10-year median of 0.26 and 72.1% below the Consumer Packaged Goods industry median of 2.08. Rohto Pharmaceutical Co's overall GF Score™ is 89/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Rohto Pharmaceutical Co (RPHCF), the current Debt-to-EBITDA is 0.58 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Rohto Pharmaceutical Co (RPHCF) Overvalued in 2026?
Based on GuruFocus' analysis, Rohto Pharmaceutical Co stock appears to be undervalued.
The current stock price of $15.00 is trading 28.7% below its estimated GF Value™ of $21.04.
Key valuation signals for RPHCF:
Debt-to-EBITDA: 0.58 (123% above median its 10-year median of 0.26)
GF Value™: $21.04 vs. price of $15.00 (28.7% below fair value)
Industry Position: 72.1% below the Consumer Packaged Goods median (#474 of 1549)
No single metric tells the full story. See the RPHCF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Rohto Pharmaceutical Co Ltd is a Japan-based company mainly engaged in the manufacture and sale of health and beauty care products. The company operates through four reportable segments: Japan, America, Europe, and Asia. Each segment manufactures and sells products related to eye care (such as eye drops and eyewash), skin care (including dermatological medications, lip balm, sunscreen, and functional cosmetics), oral medication (such as gastrointestinal and herbal medicines, and supplements), and other products such as in-vitro diagnostic reagents. It generates the majority of its revenue from Japan.
89GF Score
Get the complete analysis for RPHCF
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
RPHCF has been successfully added to your 
